International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(15), P. 12296 - 12296
Published: Aug. 1, 2023
Chronic
obstructive
pulmonary
disease
(COPD)
and
lung
cancer
17
are
two
of
the
most
prevalent
debilitating
respiratory
diseases
worldwide,
both
associated
with
high
morbidity
mortality
rates.
As
major
global
health
concerns,
they
impose
a
substantial
burden
on
patients,
healthcare
systems,
society
at
large.
Despite
their
distinct
aetiologies,
COPD
share
common
risk
factors,
clinical
features,
pathological
pathways,
which
have
spurred
increasing
research
interest
in
co-occurrence.
One
area
particular
is
role
microbiome
development
progression
these
diseases,
including
transition
from
to
cancer.
Exploring
novel
therapeutic
strategies,
such
as
metal-based
drugs,
offers
potential
avenue
for
targeting
improve
patient
outcomes.
This
review
aims
provide
an
overview
current
understanding
microbiome,
emphasis
cancer,
discuss
drugs
strategy
conditions,
specifically
concerning
microbiome.
